Openness Personality Trait Associated With Benefit From a Nonpharmacological Breathlessness Intervention in People With Intrathoracic Cancer: An Exploratory Analysis
Breathlessness is common in people with lung cancer. Nonpharmacological breathlessness interventions reduce distress because of and increase mastery over breathlessness.
VIDEO-ASSISTED thoracoscopic surgery (VATS) is used as an alternative to perform resections for lung cancer. The advantage of VATS includes less postoperative pain and fewer analgesic requirements; in addition, there is a reduction in pulmonary complications, shorter length of hospital stay after surgery, and enhanced recovery.1,2 Nevertheless, there still is a need to have an adequate management of pain control in the postoperative period to decrease the risk of pulmonary complications and post-thoracic surgery pain syndrome.
Death anxiety is common in patients with metastatic cancer, but its relationship to brain metastases and cognitive decline is unknown. Early identification of death anxiety and its determinants allows proactive interventions to be offered to those in need.
We describe the supportive medications used by treatment-na ïve lung cancer patients and assess their association with PROs from MD Anderson Symptom Inventory (MDASI).MethodsTreatment-na ïve lung cancer patients who completed PROs from MDASI at the initial visit to MD Anderson Cancer Center were included. Medications from the initial visit were abstracted from the electronic medical records system and categorized into therapeutic classes based on U.S. Pharmacopeia v7.0. A chi-squar e or Mann-WhitneyU test was conducted as appropriate.ResultsAmong 459 patients, ~ 50% took any analgesics and 25% were on opi...
I read with great interest the article of Gjeilo and colleagues in a recent issue of the journal (1). The authors completed a prospective study on 264 patients undergoing surgery for primary lung cancer and concluded that pain was highly prevalent after surgery, and subgroups could be identified based on different pain trajectories. The authors should be commended for performing a well-designed study in an important topic (e.g. pain) in patients undergoing surgery (2, 3). The need to identify the highest risk patients so specific preventive analgesic strategies can be tailored to patients who will benefit the most is a ver...
I read with great interest the article of Gjeilo et al.1 in a recent issue of the journal. The authors completed a prospective study on 264 patients undergoing surgery for primary lung cancer and concluded that pain was highly prevalent after surgery, and subgroups could be identified based on different pain trajectories. The authors should be com mended for performing a well-designed study in an important topic (e.g., pain) in patients undergoing surgery.2,3 The need to identify the highest risk patients so specific preventive analgesic strategies can be tailored to patients who will benefit the most is a ...
Breathlessness is common in people with lung cancer. Non-pharmacological breathlessness interventions reduce ‘distress due to’ and increase ‘mastery over’ breathlessness.
Over the past several years, a wave of new cancer immunotherapy agents referred to as immune checkpoint inhibitors (ICIs) have transformed the standard of care for patients with cancer. ICIs are most commonly used in advanced cancers with palliative intent and recently as frontline therapy for some cancers. These new agents have been shown to extend overall survival (OS) and progression free survival (PFS) in patients with lung cancer, melanoma, Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, head and neck cancer, and more.
Approximately 60% of cancer patients receive radiation therapy during the course of their illness, and nearly half of all patients referred to radiation oncology are treated with palliative intent. However, many palliative care specialists are unfamiliar with the indications, expected outcomes, and toxicities of radiation therapy. Palliative care providers can benefit from a greater understanding of how to support patients and their families through this process. This session will follow a patient with lung cancer from the time of diagnosis, through curative-intent treatment and subsequent recurrence with brain and bone metastases, to death.
Lung cancer is increasingly recognized as a heterogeneous disease. Recent advances in identifying genetic mutations and targeted therapies have improved the prognosis of lung cancer in patients with these mutations, yet little is known about their experiences.
Minority patients with lung cancer often have higher rates of morbidity and mortality. This leads to increased suffering among minority patients with lung cancer. Little is known, however, about disparities in supportive care needs among patients with advanced lung cancer and how these needs evolve over time.